• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Case Rep Neurol . Cerebrovascular Disease in Patients With COVID-19: A Review of the Literature and Case Series

tetano

Editor, Senior Moderator
Case Rep Neurol


. 2020 Jun 11;12(2):199-209.
doi: 10.1159/000508958. eCollection May-Aug 2020.
Cerebrovascular Disease in Patients With COVID-19: A Review of the Literature and Case Series


Sujan T Reddy[SUP] 1 2 [/SUP], Tanu Garg[SUP] 3 [/SUP], Chintan Shah[SUP] 4 [/SUP], F?bio A Nascimento[SUP] 4 [/SUP], Rajeel Imran[SUP] 3 [/SUP], Peter Kan[SUP] 5 [/SUP], Ritvij Bowry[SUP] 2 6 [/SUP], Nicole Gonzales[SUP] 1 2 [/SUP], Andrew Barreto[SUP] 1 2 [/SUP], Abhay Kumar[SUP] 6 [/SUP], John Volpi[SUP] 3 [/SUP], Vivek Misra[SUP] 3 [/SUP], David Chiu[SUP] 3 [/SUP], Rajan Gadhia[SUP] 3 [/SUP], Sean I Savitz[SUP] 1 2 [/SUP]



Affiliations

Abstract

COVID-19 has been associated with a hypercoagulable state causing cardiovascular and neurovascular complications. To further characterize cerebrovascular disease (CVD) in COVID-19, we review the current literature of published cases and additionally report the clinical presentation, laboratory and diagnostic testing results of 12 cases with COVID-19 infection and concurrent CVD from two academic medical centers in Houston, TX, USA, between March 1 and May 10, 2020. To date, there are 12 case studies reporting 47 cases of CVD in COVID-19. However, only 4 small case series have described the clinical and laboratory findings in patients with COVID-19 and concurrent stroke. Viral neurotropism, endothelial dysfunction, coagulopathy and inflammation are plausible proposed mechanisms of CVD in COVID-19 patients. In our case series of 12 patients, 10 patients had an ischemic stroke, of which 1 suffered hemorrhagic transformation and two had intracerebral hemorrhage. Etiology was determined to be embolic without a clear cause identified in 6 ischemic stroke patients, while the remaining had an identifiable source of stroke. The majority of the patients had elevated inflammatory markers such as D-dimer and interleukin-6. In patients with embolic stroke of unclear etiology, COVID-19 may have played a direct or indirect role in the processes that eventually led to the strokes while in the remaining cases, it is unclear if infection contributed partially or was an incidental finding.

Keywords: APLS; COVID-19; Cerebrovascular disease; Coronavirus; SARS-CoV-2; Stroke.
 
Back
Top Bottom